Johnson Financial Group Inc. continued to hold its stake in ResMed Inc. (NYSE:RMD) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,835 shares of the medical equipment provider’s stock at the close of the second quarter. Johnson Financial Group Inc.’s holdings in ResMed were worth $221,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RMD. Toronto Dominion Bank boosted its stake in ResMed by 26.6% during the 1st quarter. Toronto Dominion Bank now owns 1,543 shares of the medical equipment provider’s stock valued at $111,000 after purchasing an additional 324 shares in the last quarter. Creative Planning boosted its stake in ResMed by 97.1% during the 2nd quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after purchasing an additional 823 shares in the last quarter. Van ECK Associates Corp boosted its stake in ResMed by 7.5% during the 1st quarter. Van ECK Associates Corp now owns 1,945 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 136 shares in the last quarter. Huntington National Bank bought a new position in ResMed during the 2nd quarter valued at $156,000. Finally, Morgan Dempsey Capital Management LLC boosted its stake in ResMed by 2.3% during the 1st quarter. Morgan Dempsey Capital Management LLC now owns 2,189 shares of the medical equipment provider’s stock valued at $158,000 after purchasing an additional 50 shares in the last quarter. 60.25% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a research note on Thursday, July 6th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research note on Friday. Citigroup Inc. raised ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 2nd. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Finally, BidaskClub raised ResMed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $67.86.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/10/johnson-financial-group-inc-has-221000-stake-in-resmed-inc-rmd.html.

In other ResMed news, Director Gary W. Pace sold 24,390 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $76.00, for a total transaction of $1,853,640.00. Following the completion of the sale, the director now owns 99,317 shares in the company, valued at approximately $7,548,092. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Sulpizio sold 65,887 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $77.82, for a total transaction of $5,127,326.34. Following the sale, the director now owns 4,429 shares of the company’s stock, valued at approximately $344,664.78. The disclosure for this sale can be found here. Insiders have sold a total of 204,649 shares of company stock valued at $15,635,958 in the last quarter. Corporate insiders own 1.97% of the company’s stock.

ResMed Inc. (NYSE RMD) traded up 1.29% during midday trading on Friday, hitting $79.84. The stock had a trading volume of 557,663 shares. The stock’s 50-day moving average is $75.36 and its 200-day moving average is $73.06. ResMed Inc. has a one year low of $56.59 and a one year high of $80.38. The company has a market cap of $11.35 billion, a P/E ratio of 33.27 and a beta of 0.79.

ResMed (NYSE:RMD) last issued its earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, beating the consensus estimate of $0.75 by $0.02. The company had revenue of $556.69 million during the quarter, compared to analysts’ expectations of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.74 EPS. Equities analysts predict that ResMed Inc. will post $3.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be given a dividend of $0.35 per share. This is a boost from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. This represents a $1.40 annualized dividend and a dividend yield of 1.75%. ResMed’s payout ratio is presently 58.09%.

ResMed Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.